BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 9488805)

  • 1. Melanoma antigens and targets for vaccination.
    Kang N; Truman H; Sanders R; Kupsch J
    Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell vaccination as a treatment modality for melanoma.
    Eubel J; Enk AH
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1631-42. PubMed ID: 19895246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vaccine strategies against melanoma].
    Ghiringhelli F; Zitvogel L
    Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines against advanced melanoma.
    Blanchard T; Srivastava PK; Duan F
    Clin Dermatol; 2013; 31(2):179-90. PubMed ID: 23438381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaccination therapy of melanoma].
    Schuler-Thurner B; Schuler G
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):630-45. PubMed ID: 16033483
    [No Abstract]   [Full Text] [Related]  

  • 7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closing in on a melanoma skin cancer vaccine.
    Mayo Clin Health Lett; 2012 Oct; 30(10):4. PubMed ID: 23133855
    [No Abstract]   [Full Text] [Related]  

  • 9. Melanoma vaccines: achievements and perspectives.
    Brichard VG; Gérard C
    Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
    Sondak VK; Sosman JA
    Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy for melanoma: how can tolerance be overcome?].
    Robert C
    Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
    [No Abstract]   [Full Text] [Related]  

  • 12. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
    Hsueh EC; Morton DL
    Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active immunotherapy with allogeneic tumor cell vaccines: present status.
    Chan AD; Morton DL
    Semin Oncol; 1998 Dec; 25(6):611-22. PubMed ID: 9865676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination for malignant melanoma: recent developments.
    Jäger D; Jäger E; Knuth A
    Oncology; 2001; 60(1):1-7. PubMed ID: 11150901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma vaccines.
    Chapman PB
    Semin Oncol; 2007 Dec; 34(6):516-23. PubMed ID: 18083375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Sondak VK; Sabel MS; Mulé JJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.
    Gordon LK; Ribas A; Nusinowitz S; Butterfield LH; Glaspy JA; Economou JS; Straatsma BR
    Control Clin Trials; 2004 Aug; 25(4):400-7. PubMed ID: 15296814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Active specific immunotherapy of malignant melanoma].
    Lotem M; Shiloni E; Ingber A; Peretz T
    Harefuah; 1997 Aug; 133(3-4):122-6. PubMed ID: 9332080
    [No Abstract]   [Full Text] [Related]  

  • 19. DC therapy for metastatic melanoma.
    Ingram SB; O'Rourke MG
    Cytotherapy; 2004; 6(2):148-53. PubMed ID: 15203991
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.